Amedica Announces Podium Presentations and Participation at NASS 2017

Silicon Nitride to be featured in several NASS sessions

SALT LAKE CITY, Oct. 23, 2017 -- Amedica Corporation (Nasdaq:AMDA), an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced key podium presentations to be made and its participation at the annual meeting of the North American Spine Society (NASS) 2017, October 25 – 27 in Orlando, Florida. At the 2017 NASS annual meeting spine care professionals from around the globe will share the latest information, innovative techniques and procedures, best practices, and new technologies.

Amedica has had three podium presentations accepted by NASS that will be delivered by surgeon users of Amedica’s silicon nitride products. These presentations reflect the scientific and clinical advancements of Amedica’s innovative silicon nitride material. More specifically, the presentations will demonstrate silicon nitride’s innate bioactivity, osseoconductivity, and inherent antimicrobial properties.

Additionally, the company will be exhibiting at booth #905 promoting its line of Valeo® silicon nitride spinal implants and the Taurus™ pedicle screw system. Additional details can be found at https://www.amedica.com/news-media/events.

Podium Presentations
Enhanced Osseoconductivity via Endocytotic Formation of Silicon- and Nitrogen-Substituted Hydroxyapatite within the Osseous Tissue of a Retrieved Intervertebral Spinal Spacer
Presented by: Dr. Alex Gitelman, MD
Date: Wednesday, October 25, 2017
Time: 2:05 pm EST
Session: Innovative Technologies Presentation

An Assessment of the Inherent Antimicrobial Resistance of Biomaterials Utilized in Spinal Fusion Surgery
Presented by: Dr. Craig Kuhns, MD
Date: Friday, October 27, 2017
Time: 1:27 pm EST
Session:  Abstract Presentations- Infection

Enhanced Bioactivity and Bacteriostasis of PEEK Polymers Through Incorporation of Silicon Nitride Particles
Presented by: Dr. Craig Kuhns, MD
Date: Friday, October 27, 2017
Time: 1:33 pm EST
Session: Abstract Presentations- Infection

About Amedica Corporation

Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on September 20, 2017, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:
Amedica IR
801-839-3502
[email protected]